Navigation Links
FDA approves first drug for Huntington's disease
Date:8/15/2008

The U.S. Food and Drug Administration today approved tetrabenazine, the first drug approved for use in the United States to treat Huntington's disease, a fatal, inherited neurodegenerative disorder for which there is no cure. The action comes about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease.

The drug is already widely used in Europe, Canada and Australia to treat one of the most disabling symptoms of Huntington's disease, involuntary writhing movements known as chorea. Chorea is one of the trademark symptoms of the disease, which directly affects about 30,000 people in the United States today; another 70,000 people who are alive today will be diagnosed with the disease. FDA has classified tetrabenazine as an "orphan drug," since it's targeted to a disease that directly affects fewer than 200,000 people in the nation.

The pivotal study leading to the drug's approval was done by the Huntington Study Group, based at the University of Rochester Medical Center, and was led by Rochester neurologist Frederick J. Marshall, M.D. That study, published in the journal Neurology in 2006, found that the medication cut down involuntary movements on average by about 25 percent, with many patients experiencing a greater improvement. Overall, patients who received the medication were six times as likely to be considered by their doctors to have improved considerably, compared to participants who received a placebo.

"This is a huge deal," said Marshall. "Ninety percent of patients with Huntington's disease have chorea, and many suffer terribly. It's hard to describe the torment that these people undergo. We had several patients who experienced a dramatic improvement in their quality of life. Some patients who hadn't been able to attend church for years were able to do so. Others were able to go out to a restaurant and have a meal for the first time in years. It's impossible
'/>"/>

Contact: Tom Rickey
tom_rickey@urmc.rochester.edu
585-275-7954
University of Rochester Medical Center
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. The California Board of Registered Nursing Approves Affiliations for Nursing Program in Glendale, California
2. Kaiser Permanente Approves $22 Million in Community Benefit Grants in Second Quarter of 2008
3. Hillenbrand, Inc. Board of Directors Approves $100M Share Repurchase Program
4. Edwards Lifesciences Board Approves New $250 Million Share Repurchase Program
5. Congress Approves ePrescribing Initiative in Medicare Reform Bill: Critical Catalyst in Driving a New Generation of Prescribing
6. FDA Approves Genetic Test for Breast Cancer
7. FDA Approves KINRIX(TM) - New Combination Vaccine for Children
8. FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
9. Japan Approves CyberKnife System for Extracranial Use
10. FDA approves NeuRx diaphragm pacing system for use in spinal cord- injured patients
11. FDA Approves Cymbalta(R) for the Management of Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, ... and GreenGeeks are the best Dedicated Server Hosting ... who want to buy high quality hosting and ... IT manager of Top10BestSEOHosting.com says, “We believe that ... for everyone. A lot of the global clients ...
(Date:10/19/2014)... Texas (PRWEB) October 20, 2014 ... development for Partial Seizure, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ... Partial Seizure and special features on late-stage and ...
(Date:10/19/2014)... Fancyflyingfox.com, an innovative company that provides many kinds of ... of 2014 mother of the bride dresses . ... with big discounts, up to 70% off. All consumers ... this special offer. , Owing to the company’s ... of the leading brands in the global market. A ...
(Date:10/19/2014)... October 20, 2014 Stephen T. Greenberg, M.D., ... nominated for the 10th consecutive year as one of Long ... Greenberg was also been nominated as the best provider for ... nominated as best Day Spa and best Laser Treatment center ... 14th and readers can vote for the contest once per ...
(Date:10/19/2014)... 20, 2014 – The U.S. Government has initiated ... Alzheimer,s disease by 2025. However, a workgroup of ... research milestones in the U.S. Government,s National Plan ... scope, increased in scale, and adequately funded in ... of proposals by the workgroup to enlarge and ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6
... executives took their cholesterol lowering medication as prescribed by ... the executives who took their medication even sporadically were ... study finding also questions the prevailing wisdom that income ... University of Michigan researchers studied 1,607 executive level managers ...
... who join a sorority* are more likely to judge ... self-objectification) and display higher levels of bulimic attitudes and ... the sorority,s recruitment process. Over time, those women who ... shame. These findings, part of Ashley Marie Rolnik,s senior ...
... lose weight or exercise, study finds , TUESDAY, March ... developing diabetes apparently isn,t enough to make most people take ... April issue of the American Journal of Preventive Medicine ... said they had tried to drop pounds or boost their ...
... This is Part ... RN Employment Lifecycle: Engagement, Retention and High-performance, , ... CHARLOTTE, NC (Vocus) March 2, 2010 -- Morehead, the human capital ... The free hour-long webinar will be broadcast on Tuesday, March 23, 2010 at 1:00 p.m. ...
... , ... ... ... ...
... ... ... ... ...
Cached Medicine News:Health News:Even the boss doesn't follow the doctor's orders 2Health News:Only the beautiful need apply 2Health News:Having Prediabetes May Not Kick-Start Prevention Efforts 2Health News:Morehead Presents Webinar on "When Satisfaction Isn't Enough: Improving RN Engagement" 2Health News:Morehead Presents Webinar on "When Satisfaction Isn't Enough: Improving RN Engagement" 3Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 2Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 3Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 4Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 5Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 6Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 7Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 8Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 9Health News:Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis 2Health News:Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis 3Health News:Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis 4Health News:Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis 5Health News:Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis 6Health News:Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis 7Health News:Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis 8Health News:Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis 9Health News:Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis 10Health News:Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis 11Health News:Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis 12
(Date:10/19/2014)... , Deutschland, October 19, 2014 ... gefragt. Das Problem dabei ist, dass ... mit der Kompetenz zu teilen. Es ... deshalb freuen wir uns umso mehr, dass es ... ihre Gepflogenheiten bei Kühlketten aufzuschreiben - mit einem ...
(Date:10/17/2014)... 2014 With the recent changes in ... come across several challenges in creating and utilizing ... The Medical Affairs Consortium ... providing benchmarking and best practices across critical Medical ... service composed of three stages: 1) member-driven topic ...
(Date:10/17/2014)... -- Hanger, Inc. (NYSE: HGR ) announced today ... for the quarter ended September 30, 2014, on Thursday, ... call to discuss these results is scheduled to begin ... Those wishing to participate should call 1-877-662-6095. A replay ... dialing 1-855-859-2056 and referencing Conference ID # 91880739. ...
Breaking Medicine Technology:Vergleichsbericht zu Pharma-Kühlketten und CRT 2Early Key Findings from the Medical Affairs Consortium Research 2
... Antibacterial Products aimed at reducing cross contamination ... infections ... Corporation,announced today the SILVER SEAL(TM) family of antibacterial products for,infection ... and Mouse. According to the company, the,SILVER SEAL(TM) Keyboard and ...
... - Once Granted by the European Commission, ATRIPLA Would Represent the, First ... ... Union -, PRINCETON, N.J., FOSTER CITY, Calif. and WHITEHOUSE STATION, N.J., ... GILD ) and Merck & Co., Inc. (NYSE: MRK ),announced ...
Cached Medicine Technology:Seal Shield Launches World's First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control 2Seal Shield Launches World's First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control 3European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 2European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 3European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 4European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 5European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 6European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 7European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 8European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 9European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 10
Selute Picotip Atrial-J steroid eluting passive fixation lead...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: